• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by CareDx Inc.

    8/21/24 9:00:35 PM ET
    $CDNA
    Medical Specialities
    Health Care
    Get the next $CDNA alert in real time by email
    SC 13G/A 1 caredx_13ga2.htm
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. 2)*
     
    CareDx, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
     
    14167L103
    (CUSIP Number)
     
    August 20, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    o Rule 13d-1(b)
    x Rule 13d-1(c)
    o Rule 13d-1(d)
       

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).  

     
     
    CUSIP No. 14167L103 13G Page 2 of 8

     

                 
    1.

    Names Of Reporting Persons

    Gagnon Securities LLC

     

     
           
    2. check the appropriate box if a group (a) o
    (b) x

    3. sec use only    
           
    4.

    citizenship or place of organization

     

    Delaware Limited Liability Company

     

       
    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with:
    5. sole voting power     0
    6. shared voting power     1,542,114
    7. sole dispositive power     0
    8. shared dispositive power     1,847,226
    9. aggregate amount beneficially owned by each reporting person   1,847,226
    10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o
    11. percent of class represented by amount in row (9)  

    3.5%

    12. type of reporting person (See Instructions)     IA, BD

     

     
     
     
    CUSIP No. 14167L103 13G Page 3 of 8

     

                 
    1.

    Names Of Reporting Persons

    Gagnon Advisors, LLC

     

     
           
    2. check the appropriate box if a group (a) o
    (b) x

    3. sec use only    
           
    4.

    citizenship or place of organization

     

    Delaware Limited Liability Company

     

       
    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with:
    5. sole voting power     0
    6. shared voting power     430,819
    7. sole dispositive power     0
    8. shared dispositive power    

    430,819

    9. aggregate amount beneficially owned by each reporting person  

    430,819

    10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o
    11. percent of class represented by amount in row (9)  

    0.8%

    12. type of reporting person (See Instructions)     IA

     

     
     
     
    CUSIP No. 14167L103 13G Page 4 of 8

     

                 
    1.

    Names Of Reporting Persons

    Neil Gagnon

     

     
           
    2. check the appropriate box if a group (a) o
    (b) x

    3. sec use only    
           
    4.

    citizenship or place of organization

     

    USA

     

       
    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with:
    5. sole voting power    

    154,071

    6. shared voting power    

    2,081,995

    7. sole dispositive power    

    154,071

    8. shared dispositive power    

    2,395,507

    9. aggregate amount beneficially owned by each reporting person  

    2,549,578

    10. check box if the aggregate amount in row (9) excludes certain shares (See Instructions) o
    11. percent of class represented by amount in row (9)  

    4.8%

    12. type of reporting person (See Instructions)     IN

     

     
     
     
    CUSIP No. 14167L103 13G Page 5 of 8
    Item 1.  

     

    (a) Name of Issuer: CareDx, Inc.
         
    (b) Address of Issuer’s Principal

    8000 Marina Blvd, 4th Floor

      Executive Offices:

    Brisbane, California 94005

     

    Item 2.

    (a) Name of Person Filing:

    Neil Gagnon has sole voting and dispositive power over 154,071 shares of the Issuer’s Common Stock, par value $0.001 per share (the “Common Stock”). In addition, Mr. Gagnon has shared voting power over 2,081,995 shares of Common Stock and shared dispositive power over 2,395,507 shares of Common Stock.

     

    Mr. Gagnon is the managing member and principal owner of Gagnon Securities LLC (“GS”), an investment adviser registered with the U.S. Securities and Exchange Commission (“SEC”) under the Investment Advisers Act of 1940, as amended (the “Advisers Act”), and a registered broker-dealer, in its role as investment manager to several customer accounts, foundations, partnerships and trusts (collectively, the “Accounts”) to which it furnishes investment advice. GS and Mr. Gagnon may be deemed to share voting power with respect to 1,542,114 shares of Common Stock held in the Accounts and dispositive power with respect to 1,847,226 shares of Common Stock held in the Accounts. GS and Mr. Gagnon expressly disclaim beneficial ownership of all securities held in the Accounts.

     

    Mr. Gagnon is also the Chief Executive Officer of Gagnon Advisors, LLC (“Gagnon Advisors”), an investment adviser registered with the SEC under the Advisers Act. Mr. Gagnon and Gagnon Advisors, in its role as investment manager to Gagnon Investment Associates, LLC (“GIA”), a private investment fund, may be deemed to share voting and dispositive power with respect to the 430,819 shares of Common Stock held by GIA. Gagnon Advisors and Mr. Gagnon expressly disclaim beneficial ownership of all securities held by GIA.

     

    (b) Address of Principal Business Office 1370 Ave. of the Americas, 26th Floor
      or, if none, Residence: New York, NY 10019

     

    (c) Citizenship:

    Gagnon Securities LLC

    Delaware Limited Liability Company

       

    Gagnon Advisors, LLC

    Delaware Limited Liability Company

       

    Neil Gagnon

    USA

         
    (d) Title of Class of Securities:

    Common Stock, par value $0.001 per share

         
    (e) CUSIP Number: 14167L103

     

     
     
     
    CUSIP No. 14167L103 13G Page 6 of 8
       
    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:

     

    (a)  o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
         
    (b)  o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
         
    (c)  o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
         
    (d)  o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
         
    (e)  o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f)  o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g)  o A parent holding company or control person in accordance with § 13d-1(b)(1)(ii)(G);
         
    (h)  o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i)  o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15U.S.C. 80a-3);
         
    (j)  o A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
         
    (k)  o Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

     
     
     
    CUSIP No. 14167L103 13G Page 7 of 8
    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned:

    Gagnon Securities LLC

    1,847,226

         

    Gagnon Advisors, LLC

    430,819

         

    Neil Gagnon

    2,549,578

           
      (b) Percent of class:

    Gagnon Securities LLC

    3.5%

         

    Gagnon Advisors, LLC

    0.8%

         

    Neil Gagnon

    4.8%

           
         

    Calculation of percentage of beneficial ownership is based on 52,740,008 shares outstanding as of July 29, 2024, as disclosed in the Issuer’s Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on July 31, 2024.

           
      (c) Number of shares as to which the person has:

     

      (i) Sole power to vote or to direct the vote:

    Gagnon Securities LLC

    0

         

    Gagnon Advisors, LLC

    0
         

    Neil Gagnon

    154,071

           
      (ii) Shared power to vote or to direct the vote:

    Gagnon Securities LLC

    1,542,114

         

    Gagnon Advisors, LLC

    430,819

         

    Neil Gagnon

    2,081,995

           
      (iii) Sole power to dispose or to direct the disposition of:

    Gagnon Securities LLC

    0
         

    Gagnon Advisors, LLC

    0
         

    Neil Gagnon

    154,071

           
      (iv) Shared power to dispose or to direct the disposition of:

    Gagnon Securities LLC

    1,847,226

         

    Gagnon Advisors, LLC

    430,819

         

    Neil Gagnon

    2,395,507

     

    Item 5. Ownership of Five Percent or Less of a Class.
       

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    The Accounts described above in Item 2 have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, securities held in their respective accounts. To the knowledge of the Reporting Persons the interest in any such account does not exceed 5% of the class of securities. Except to the extent described herein, the Reporting Person disclaims beneficial ownership of all such securities.

     

    Items 7 – 9. Not Applicable.

     

     
     
     
    CUSIP No. 14167L103 13G Page 8 of 8
       
    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Section 230.14a-11.

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: August 21, 2024

       
      NEIL GAGNON
     
     

    /s/ Neil Gagnon

       
     

    GAGNON SECURITIES LLC

       
     

    /s/ Neil Gagnon

      Name:  Neil Gagnon 
     

    Title:    Managing Member

       
     

    GAGNON ADVISORS, LLC

       
     

    /s/ Neil Gagnon

      Name:  Neil Gagnon 
     

    Title:    Chief Executive Officer

       
     
     
    Get the next $CDNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDNA

    DatePrice TargetRatingAnalyst
    1/15/2025$28.00 → $24.00Underweight → Equal Weight
    Wells Fargo
    8/28/2024$28.00Underweight
    Wells Fargo
    8/19/2024$40.00Neutral → Buy
    BTIG Research
    5/13/2024Outperform → Mkt Perform
    Raymond James
    5/1/2024$15.00Hold → Buy
    Craig Hallum
    11/9/2023$10.00Equal-Weight → Overweight
    Stephens
    8/15/2023$12.00Mkt Perform → Outperform
    Raymond James
    5/11/2023Buy → Neutral
    BTIG Research
    More analyst ratings

    $CDNA
    SEC Filings

    See more
    • SEC Form 144 filed by CareDx Inc.

      144 - CareDx, Inc. (0001217234) (Subject)

      5/12/25 5:15:18 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • SEC Form 144 filed by CareDx Inc.

      144 - CareDx, Inc. (0001217234) (Subject)

      5/12/25 5:10:58 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • SEC Form 144 filed by CareDx Inc.

      144 - CareDx, Inc. (0001217234) (Subject)

      5/6/25 5:00:40 PM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CareDx upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded CareDx from Underweight to Equal Weight and set a new price target of $24.00 from $28.00 previously

      1/15/25 7:29:19 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • Wells Fargo initiated coverage on CareDx with a new price target

      Wells Fargo initiated coverage of CareDx with a rating of Underweight and set a new price target of $28.00

      8/28/24 7:38:28 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx upgraded by BTIG Research with a new price target

      BTIG Research upgraded CareDx from Neutral to Buy and set a new price target of $40.00

      8/19/24 8:49:21 AM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cournoyer Christine sold $235,929 worth of shares (16,700 units at $14.13), decreasing direct ownership by 31% to 37,045 units (SEC Form 4)

      4 - CareDx, Inc. (0001217234) (Issuer)

      5/8/25 4:31:15 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • Secretary and General Counsel Novack Jeffrey Adam sold $39,514 worth of shares (2,688 units at $14.70), decreasing direct ownership by 2% to 121,350 units (SEC Form 4)

      4 - CareDx, Inc. (0001217234) (Issuer)

      5/7/25 4:38:39 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • Secretary and General Counsel Novack Jeffrey Adam covered exercise/tax liability with 2,873 shares, decreasing direct ownership by 2% to 124,038 units (SEC Form 4)

      4 - CareDx, Inc. (0001217234) (Issuer)

      5/5/25 4:53:42 PM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by CareDx Inc.

      SC 13G/A - CareDx, Inc. (0001217234) (Subject)

      11/14/24 5:13:57 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CareDx Inc.

      SC 13G/A - CareDx, Inc. (0001217234) (Subject)

      11/8/24 2:34:10 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CareDx Inc.

      SC 13G/A - CareDx, Inc. (0001217234) (Subject)

      11/5/24 6:07:26 AM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    Leadership Updates

    Live Leadership Updates

    See more
    • CareDx Appoints Jing Huang Chief Data and AI Officer

      CareDx, Inc. (NASDAQ:CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the appointment of Jing Huang Ph.D., in the newly created role of Chief Data and Artificial Intelligence (AI) Officer. Huang will lead key data science initiatives that are a part of the Company's long-term strategic growth plan. CareDx intends to share its long-term growth strategy during an Investor Day on October 15, 2024. Huang is a recognized leader in data science and machine learning, bringing to CareDx a proven trac

      10/9/24 7:05:00 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Appoints Keith Kennedy Chief Operating Officer and Jessica Meng Chief Commercial Officer

      CareDx Announces Addition of Operational and Commercial Expertise to Lead Key Strategic Initiatives Marica Grskovic Appointed Chief Strategy Officer to Lead Corporate Development CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the appointment of two senior executives who will lead key initiatives as the Company advances its long-term strategic growth plan. CareDx will be sharing its long-term growth strategy during an Investor Day in October 2024. Keith Kennedy brings more than 20 years of experience and e

      9/12/24 7:01:00 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Appoints John W. Hanna as its New President and Chief Executive Officer

      CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – has appointed John W. Hanna as its new President and Chief Executive Officer, and member of the Company's Board of Directors, effective April 15, 2024. "John is an outstanding leader with a proven track record of building high-performing teams that deliver consistent results. With extensive experience in the molecular diagnostics and life sciences tools industries, John is the right executive to bring strategic leadership to CareDx to propel the compan

      4/16/24 4:02:00 PM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CareDx Reports First Quarter 2025 Results

      First Quarter Revenue of $84.7 Million, Increased 18% Year-Over-Year Grew Testing Services Volume to Approximately 47,100, Marking Seventh Consecutive Quarter of Sequential Testing Services Volume Growth CareDx, Inc. (NASDAQ:CDNA) today reported financial results for the first quarter ended March 31, 2025. First Quarter Financial Highlights Reported first quarter revenue of $84.7 million, increased 18% year-over-year Testing services revenue of $61.9 million, increased 15% year-over-year, and testing services volume of approximately 47,100, increased 12% year-over-year GAAP net loss of $10.4 million, non-GAAP net income of $5.4 million, and positive adjusted EBITDA of $4.6 million,

      4/30/25 4:05:00 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

      CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ ("CareDx" or the "Company")— a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on April 7, 2025, CareDx granted to Jennifer Foley, the Company's newly appointed Chief Product Officer, certain stock awards as an inducement material to Ms. Foley's employment with CareDx. CareDx granted Ms. Foley 36,231 restricted stock units ("RSUs") pursuant to the Company's 2016 Inducement Equity Incentive Plan, which was approved by the Compensation Committee of the Company's Board o

      4/21/25 4:01:00 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx to Report First Quarter 2025 Financial Results

      CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-445-7795 for domestic callers or 1-785-424-1699 for international callers. Please reference Conference ID: CareDx. To listen to the webcast, please

      4/8/25 7:05:00 AM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    Financials

    Live finance-specific insights

    See more
    • CareDx to Report First Quarter 2025 Financial Results

      CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-445-7795 for domestic callers or 1-785-424-1699 for international callers. Please reference Conference ID: CareDx. To listen to the webcast, please

      4/8/25 7:05:00 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx to Report Fourth Quarter and Full Year 2024 Financial Results

      CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2024 after market close on Wednesday, February 26, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-267-6316 for domestic callers or 1-203-518-9783 for international callers. Please reference Conference ID: CareDx. To listen to

      2/11/25 7:05:00 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Reports Preliminary Financial Results for Third Quarter 2024

      Third Quarter 2024 Financial Results to be Reported on November 4, 2024 CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers —today reported preliminary financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Third quarter revenue is expected to be in the range of $82 million to $83 million, an increase of approximately 23% year-over-year. Grew Testing Services volume to approximately 44,600, an increase of approximately 16% year-over-year. Testi

      10/15/24 6:00:00 AM ET
      $CDNA
      Medical Specialities
      Health Care